TY - JOUR AU - Chang, Chun-Hung AU - Tsai, Hsin-Chi AU - Wu, Sheng-Nan AU - Tan, Han-Ru AU - Liu, Wen-Chun TI - Obesity and autonomic dysfunction in schizophrenia: Associations with symptom severity and onset subtypes JF - JOURNAL OF PSYCHIATRIC RESEARCH J2 - J PSYCHIATR RES VL - 191 PY - 2025 SP - 77 EP - 86 PG - 10 SN - 0022-3956 DO - 10.1016/j.jpsychires.2025.09.025 UR - https://m2.mtmt.hu/api/publication/36913927 ID - 36913927 AB - Background: Schizophrenia (SCZ) is associated with elevated cardiometabolic risk, including obesity and autonomic dysfunction. Reduced heart rate variability (HRV), reflecting impaired autonomic nervous system (ANS) function, is linked to increased mortality. Methods: Seventy inpatients with SCZ were evaluated using the Positive and Negative Syndrome Scale (PANSS). HRV was measured via a standardized 5-min protocol evaluating ANS balance, vagal activity (VAG), and standard deviation of normal-to-normal intervals (SDNN). HRV data from 112 age-matched healthy controls were included for comparison. Results: SCZ patients exhibited significantly reduced SDNN compared to controls (17.8 ms vs. 40.5 ms, p < 0.001). Older individuals with obesity exhibited higher HRV than younger, non-obese patients (SDNN: 27.8 ms vs. 14.3 ms, p = 0.019). Early-onset SCZ patients with BMI <24 showed higher PANSS-N (28.3 vs. 22.1, p = 0.012) and PANSS-G scores (41.0 vs. 35.9, p = 0.049) without HRV differences. Conversely, late-onset cases, especially among non-obese patients, was associated with better ANS and VAG indices (ANS: PCC = 0.643, p = 0.01; VAG, PCC = 0.581, p = 0.023). Males had higher white blood cell counts, while females with BMI <24 showed higher PANSS-N scores (p < 0.05). Use of long-acting injectable antipsychotics was linked to higher PANSS-S in non-obese patients (7.4 vs. 4.1, p = 0.036). Conclusion: Autonomic dysfunction is evident in SCZ, particularly in younger, non-obese individuals, and correlates with symptom severity and onset patterns. HRV and ANS metrics may serve as physiomarkers for risk stratification and personalized care. LA - English DB - MTMT ER - TY - JOUR AU - Khanmohammadi, R. AU - Mirali, H. AU - Mohammadzadeh, H. AU - Ebrahimi, S. AU - Shaw, I. AU - Shaw, B.S. TI - Randomised active controlled trial examining effects of aerobic exercise, cognitive and music interventions on depression, balance and mobility in schizophrenia JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 15 PY - 2025 IS - 1 SN - 2045-2322 DO - 10.1038/s41598-025-05024-x UR - https://m2.mtmt.hu/api/publication/36273155 ID - 36273155 N1 - Department of Motor Behavior and Sport Management, Faculty of Sports Sciences, Urmia University, West Azarbaijan Province, Urmia City, Iran School of Sport, Rehabilitation and Exercise Sciences, University of Essex, Wivenhoe Park, Essex, Colchester, United Kingdom Division of Public Health, University of the Free State, Bloemfontein, 9300, South Africa Export Date: 30 July 2025; Cited By: 0; Correspondence Address: B.S. Shaw; School of Sport, Rehabilitation and Exercise Sciences, University of Essex, Colchester, Wivenhoe Park, Essex, United Kingdom; email: b.shaw@essex.ac.uk LA - English DB - MTMT ER - TY - JOUR AU - Ricci, V. AU - Sarni, A. AU - Martinotti, G. AU - Maina, G. TI - Comparative analysis of third-generation antipsychotics in first-episode schizophrenia: Efficacy, safety, and cognitive impacts. A narrative review JF - INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY J2 - INT CLIN PSYCHOPHARMACOL VL - 40 PY - 2025 IS - 4 SP - 191 EP - 206 PG - 16 SN - 0268-1315 DO - 10.1097/YIC.0000000000000559 UR - https://m2.mtmt.hu/api/publication/36273154 ID - 36273154 N1 - Department of Psychiatry, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy Department of Neurosciences Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio Chieti-Pescara, Chieti, Italy Department of Neurosciences 'Rita Levi Montalcini', University of Turin, Torino, Italy Export Date: 30 July 2025; Cited By: 5; Correspondence Address: V. Ricci; San Luigi Gonzaga Hospital, University of Turin, Orbassano, Regione Gonzole 10, TO, 10043, Italy; email: v.ricci@sanluigi.piemonte.it; CODEN: ICLPE LA - English DB - MTMT ER - TY - JOUR AU - Balicza, Péter AU - Gézsi, András AU - Fedor, Mariann AU - C. Sági, Judit AU - Gál, Anikó AU - Varga, Noémi-Ágnes AU - Molnár, Mária Judit TI - Multilevel evidence of MECP2-associated mitochondrial dysfunction and its therapeutic implications JF - FRONTIERS IN PSYCHIATRY J2 - FRONT PSYCHIATRY VL - 14 PY - 2024 PG - 13 SN - 1664-0640 DO - 10.3389/fpsyt.2023.1301272 UR - https://m2.mtmt.hu/api/publication/34484128 ID - 34484128 AB - We present a male patient carrying a pathogenic MECP2 p. Arg179Trp variant with predominant negative psychiatric features and multilevel evidence of mitochondrial dysfunction who responded to the cariprazine treatment. He had delayed speech development and later experienced severe social anxiety, learning disabilities, cognitive slowing, and predominant negative psychiatric symptoms associated with rigidity. Clinical examinations showed multisystemic involvement. Together with elevated ergometric lactate levels, the clinical picture suggested mitochondrial disease, which was also supported by muscle histopathology. Exploratory transcriptome analysis also revealed the involvement of metabolic and oxidative phosphorylation pathways. Whole-exome sequencing identified a pathogenic MECP2 variant, which can explain both the dopamine imbalance and mitochondrial dysfunction in this patient. Mitochondrial dysfunction was previously suggested in classical Rett syndrome, and we detected related phenotype evidence on multiple consistent levels for the first time in a MECP2 variant carrier male. This study further supports the importance of the MECP2 gene in the mitochondrial pathways, which can open the gate for more personalized therapeutic interventions. Good cariprazine response highlights the role of dopamine dysfunction in the complex psychiatric symptoms of Rett syndrome. This can help identify the optimal treatment strategy from a transdiagnostic perspective instead of a classical diagnostic category. LA - English DB - MTMT ER - TY - JOUR AU - Selvan, P. AU - Devkare, P. AU - Shetty, A. AU - Dharmadhikari, S. AU - Khandhedia, C. AU - Mane, A. AU - Mehta, S. AU - Andrade, C. TI - A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia JF - FRONTIERS IN PSYCHIATRY J2 - FRONT PSYCHIATRY VL - 15 PY - 2024 SN - 1664-0640 DO - 10.3389/fpsyt.2024.1385925 UR - https://m2.mtmt.hu/api/publication/34859218 ID - 34859218 N1 - Department of Psychiatry, Sneka Mind Care Hospital, Tamil Nadu, Tirunelveli, India Medical Affairs and Clinical Research, Sun Pharmaceutical Industries Limited, Mumbai, India Medical Affairs and Clinical Research, Sun Pharma Laboratories Limited, Mumbai, India Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India Export Date: 16 May 2024 Correspondence Address: Devkare, P.; Medical Affairs and Clinical Research, India; email: PrashantH.Devkare@sunpharma.com LA - English DB - MTMT ER - TY - JOUR AU - Pappa, S. AU - Kalniunas, A. AU - Maret, J. TI - Cariprazine for negative symptoms in early psychosis: a pilot study with a 6-month follow-up JF - FRONTIERS IN PSYCHIATRY J2 - FRONT PSYCHIATRY VL - 14 PY - 2023 SN - 1664-0640 DO - 10.3389/fpsyt.2023.1183912 UR - https://m2.mtmt.hu/api/publication/34078666 ID - 34078666 N1 - Export Date: 27 July 2023 Correspondence Address: Pappa, S.; West London NHS TrustUnited Kingdom; email: sofia.pappa@westlondon.nhs.uk LA - English DB - MTMT ER - TY - JOUR AU - Csehi, Réka AU - Dombi, Zsófia Borbála AU - Sebe, B AU - Molnár, Mária Judit TI - Real-life clinical experience with cariprazine: a systematic review of case studies JF - FRONTIERS IN PSYCHIATRY J2 - FRONT PSYCHIATRY VL - 13 PY - 2022 PG - 17 SN - 1664-0640 DO - 10.3389/fpsyt.2022.827744 UR - https://m2.mtmt.hu/api/publication/32692122 ID - 32692122 LA - English DB - MTMT ER - TY - JOUR AU - Morozov, P. AU - Bekker, R. AU - Bykov, Y. TI - Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective JF - FRONTIERS IN PSYCHIATRY J2 - FRONT PSYCHIATRY VL - 13 PY - 2022 SN - 1664-0640 DO - 10.3389/fpsyt.2022.868751 UR - https://m2.mtmt.hu/api/publication/33035980 ID - 33035980 N1 - Cited By :2 Export Date: 27 July 2023 Correspondence Address: Morozov, P.; Pirogov Russian National Research Medical UniversityRussian Federation; email: prof.morozov@gmail.com LA - English DB - MTMT ER - TY - JOUR AU - Németh, György AU - Dombi, Zsófia Borbála AU - Laszlovszky, István AU - Barabássy, Ágota TI - Addressing negative symptoms of schizophrenia pharmacologically with cariprazine: evidence from clinical trials, a real-world study, and clinical cases JF - EXPERT OPINION ON PHARMACOTHERAPY J2 - EXPERT OPIN PHARMACO VL - 23 PY - 2022 IS - 12 SP - 1467 EP - 1468 PG - 2 SN - 1465-6566 DO - 10.1080/14656566.2021.1968827 UR - https://m2.mtmt.hu/api/publication/32183985 ID - 32183985 LA - English DB - MTMT ER - TY - JOUR AU - Rancans, Elmars AU - Dombi, Zsófia Borbála AU - Barabássy, Ágota TI - Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia JF - FRONTIERS IN PSYCHIATRY J2 - FRONT PSYCHIATRY VL - 12 PY - 2022 PG - 9 SN - 1664-0640 DO - 10.3389/fpsyt.2021.770234 UR - https://m2.mtmt.hu/api/publication/32694111 ID - 32694111 N1 - Cited By :6 Export Date: 4 July 2023 Correspondence Address: Rancans, E.; Department of Psychiatry and Narcology, Latvia; email: elmars.rancans@rsu.lv AB - Although the optimal dosing of an antipsychotic medication is known to be essential in the long-term management of schizophrenia, in case of novel drugs such as cariprazine, determining the right dosing strategy is not that simple. Without decades of experience with a particular compound, evidence regarding dosing and titration comes primarily from double-blind, placebo controlled clinical trials that are not necessarily mirroring the real-life experiences of doctors. Via summarizing data from both clinical data (n = 3275) and real-world evidence (observational study n = 116, case studies n = 29), this perspective paper aims to shed a light on the appropriate dosing strategies of cariprazine from treatment initiation through switching strategies to concomitant medications. LA - English DB - MTMT ER - TY - JOUR AU - Viegas, Filipa AU - Ferreira, Tiago AU - Campos, Claudia TI - Using Cariprazine to Ameliorate Negative Symptoms and Metabolic Side Effects of Clozapine and Paliperidone-Clinical Cases JF - NEUROPSYCHIATRIC DISEASE AND TREATMENT J2 - NEUROPSYC DISEASE TREAT VL - 18 PY - 2022 SP - 1145 EP - 1149 PG - 5 SN - 1176-6328 DO - 10.2147/NDT.S343747 UR - https://m2.mtmt.hu/api/publication/33035975 ID - 33035975 N1 - Cited By :2 Export Date: 27 July 2023 Correspondence Address: Viegas, F.; Mental Health Department Hospital Prof. Dr. Fernando Fonseca, IC-19, Portugal; email: filipaviegas1991@gmail.com AB - Introduction: Cariprazine is a third-generation antipsychotic approved in Europe in 2017 for the treatment of schizophrenia. It presents distinct pharmacodynamic properties, such as D3/D2 partial agonism, preferential binding to D3 receptors, antagonism at the serotonin 5-HT2A and 5-HT2B receptors, partial agonism at 5-HT1A receptors, and low affinity to other receptors (including noradrenergic, histaminergic, and cholinergic). It has demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia with a safe side effect and metabolic profile. Methods: Here, we describe one clinical case of a patient that benefited from an add-on of cariprazine to a regimen of clozapine; and two clinical cases of patients that benefited from the switch from clozapine and paliperidone long-acting injectable to cariprazine. Results and Discussion: Those cases illustrate how cariprazine can be used in patients with schizophrenia in the treatment of both positive and negative symptoms, and when aiming to ameliorate the metabolic burden associated with other treatments. However, further studies are needed to consubstantiate those findings. LA - English DB - MTMT ER - TY - JOUR AU - Reznik, A.M. AU - Arbuzov, A.L. AU - Murin, S.P. AU - Pavlichenko, A.V. TI - Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment JF - CONSORTIUM PSYCHIATRICUM J2 - CONSORT PSYCHIATR VL - 1 PY - 2020 IS - 2 SP - 43 EP - 51 PG - 9 SN - 2712-7672 DO - 10.17650/2712-7672-2020-1-2-43-51 UR - https://m2.mtmt.hu/api/publication/34078668 ID - 34078668 N1 - Moscow National University of Food Production, Moscow, Russian Federation Mental-health Clinic No. 1 named after N.A. Alexeev, Moscow, Russian Federation Mental Health Clinic No. 5, Khotkovo, Russian Federation Export Date: 27 July 2023 Correspondence Address: Reznik, A.M.; Moscow National University of Food ProductionRussian Federation; email: a.m.reznik1969@gmail.com LA - English DB - MTMT ER -